Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition
London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Siggi Olafsson, Hikma’s CEO, said: “Hikma continues to make strategic progress, positioning the business for future growth through new product launches, continued investment in R&D, and new strategic partnerships and acquisitions, which are all driving our […]
Related Posts
